PAMU
BIO icon

Pictet Asset Management (UK)’s Bio-Rad Laboratories Class A BIO Stock Holding History

Pictet Asset Management (UK)’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-52,000
Closed -$17.3M – 1114
2019
Q3 		$17.3M Buy
+52,000
New +$17M 0.04% 421
2019
Q2 		– Sell
-100,000
Closed -$30.6M – 1020
2019
Q1 		$30.6M Buy
+100,000
New +$27M 0.07% 319

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Pictet Asset Management (UK)'s BIO Position: Q2 2021 in Review

Pictet Asset Management (UK) reduced its Bio-Rad Laboratories Class A (BIO) stake by 29% in Q2 2021, selling an estimated $30.3M and leaving 123,071 shares worth $79.3M. The position accounts for 0.09% of the portfolio, ranked #263.

Pictet Asset Management (UK) first reported a position in BIO in Q3 2018 and has held it in 12 quarters since. The position peaked at $108M in Q3 2020. 509 funds tracked by Wall St. Rank hold BIO as of Q2 2021.

  • Pictet Asset Management (UK) held 123,071 shares of Bio-Rad Laboratories Class A worth $79.3M as of Q2 2021.
  • Pictet Asset Management (UK) sold 49,789 Bio-Rad Laboratories Class A shares in Q2 2021, an estimated $30.3M.
  • Bio-Rad Laboratories Class A made up 0.09% of Pictet Asset Management (UK)'s portfolio in Q2 2021, its #263 holding.
  • Pictet Asset Management (UK) first reported a position in Bio-Rad Laboratories Class A in Q3 2018 and has held it in 12 quarters since.
  • Pictet Asset Management (UK)'s Bio-Rad Laboratories Class A position peaked at $108M in Q3 2020.
  • 509 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2021.

Based on Pictet Asset Management (UK)'s 13F filing for Q2 2021, filed 16 Aug 2021.